Accumulation of Azithromycin and Roxithromycin in Tracheal Epithelial Fetal Cell Lines Expressing Wild Type or Mutated Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR)

References

• Quinton PM. Physiological basis of cystic fibrosis: a his-torical perspective. Physiol Rev 1999; 79 Suppl: S3-S22.
   Google Scholar
• DereIle J. [Anti-inflammatory therapy in cystic fibrosis][Article in French] Arch Pediatr 2003; 10 Suppl 2: 370s-375s.
   Google Scholar
• Martinez FJ, Simon RH. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Curr Pharm Des 2004; 10 (25): 3095–110.
   PubMed Web of Science ®Google Scholar
• Carey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflamma-tory sinopulmonary diseases. Chest 2003; 123 (1): 261–5.
   PubMed Web of Science ®Google Scholar
• Hansen CR, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005; 4: 35–40.
   PubMedGoogle Scholar
• Siddiqui J. Immunomodulatory effects of macrolides: implications for practicing clinicians. Am J Med 2004; 117 Suppl 9A: 26S-29S.
   Google Scholar
• Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13 (1): 3–8.
   PubMed Web of Science ®Google Scholar
• Labro MT. Cellular and molecular effects of macrolides Current Pharmaceut Design 2004; 10, (25): 3067-3080.
   Google Scholar
• Labro MT. Cellular accumulation of macrolide antibi-otics. Intracellular bioactivity. In: Schönfeld W, Kirst H (Eds.). Macrolide Antibiotics. Birkhauser Verlag AG. 2002: 37-52.
   Google Scholar
• Vazifeh D, Abdelghaffar H, Labro MT. Cellular accu-mulation of the new ketolide RU 64004 by human neu-trophils: comparison with that of azithromycin and rox-ithromycin. Antimicrob Agents Chemother 1997; 41: 2099-2107.
   Google Scholar
• Vazifeh D, Preira A, Bryskier A, Labro MT. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944-1951.
   Google Scholar
• Labro MT, Abdelghaffar H, Babin-Chevaye C. Interaction between the new ketolide, ABT-773 (cethromycin) and human polymorphonuclear neutrophils and the phagocyt-ic cell line PLB-985 in vitro. Antimicrob Agents Chemother 2004; 48: 1096-1104.
   Google Scholar
• Abdelghaffar H, Soukri A, Babin-Chevaye C, Labro MT. Interaction of macrolides and ketolides with the phagocyt-ic cell line PLB-985. J Chemother 2003; 15 (4): 350–356.
   PubMed Web of Science ®Google Scholar
• Endicott JA, Ling V. The biochemistry of P-glycopro-tein-mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137–171.
   PubMed Web of Science ®Google Scholar
• Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmac 1996; 27: 1283–1291.
   PubMedGoogle Scholar
• Wakasugi H, Yano I, Ito T, et al. Effect of clar-ithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123–128.
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressant FK506 and rapamycin function as reversal agents of the mul-tidrug-resistance phenotype. Blood 1992; 80: 1528-1536.
   Google Scholar
• Crosta L, Candiloro V, Meli M, Tolomeo M, Rausa L, Dusonchet. Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res 1994; 14: 2685-2690.
   Google Scholar
• Saeki T, Ueda K, Tanigawara Y, Hon i R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–6080.
   PubMed Web of Science ®Google Scholar
• Lemnanouar M, Chastre E, Paul A, et al. Oncogene-mediated propagation of tracheal epithelial cells from two cys-tic fibrosis fetuses with different mutations. Characterization of CFT-1 and CFT-2 cells in culture. Eur J Clin Invest 1993; 23 (3): 151-160.
   Google Scholar
• Mergey M, Lemnaouar M, Veissiere D, et al. CFTR gene transfer corrects defective glycoconjugate secretion in human CF epithelial tracheal cells. Am J Physiol 1995; 269 (13): L855–L864.
   PubMedGoogle Scholar
• Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake, localization and activity of fluoro-quinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26 (Suppl. B): 27-39.
   Google Scholar
• Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004; 125 (2 Suppl): 70S-78S.
   Google Scholar
• Schultz MJ. Macrolide activities beyond their antimicro-bial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54 (1): 21–28.
   PubMed Web of Science ®Google Scholar
• Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am J Respir Med 2002; 1 (4): 235–241.
   PubMedGoogle Scholar
• Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J 2004; 24 (5): 834–838.
   PubMed Web of Science ®Google Scholar
• Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10 (6): 515–523.
   PubMed Web of Science ®Google Scholar
• Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibrosis 2003; 2 (2): 69–71.
   PubMedGoogle Scholar
• Mtairag EM, Abdelghaffar H, Douhet C, Labro MT. Role of extracellular calcium in in vitro uptake and intraphago-cytic location of macrolides. Antimicrob Agents Chemother 1995; 39: 1676–1682.
   PubMed Web of Science ®Google Scholar
• Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83 (9): 2451–2458.
   PubMed Web of Science ®Google Scholar
• Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoiet-ic cells. Cancer Res 1994; 54 (17): 4676–4679.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19 (19): 5417–5423.
   PubMed Web of Science ®Google Scholar
• Graff I, Schram-Doumont A, Szpirer C. Defective pro-tein kinase C-mediated actions in cystic fibrosis neutrophils. Cell Signal 1991; 3 (3): 259–266.
   PubMed Web of Science ®Google Scholar
• Hudson VM. New insights into the pathogenesis of cys-tic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004; 3: 353–363.
   PubMedGoogle Scholar
• Dormer RL, Harris CM, Clark Z, et al. Sildenafil article (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55–59.
   PubMed Web of Science ®Google Scholar
• Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 2004; 10: 547–552.
   PubMed Web of Science ®Google Scholar
• Labro MT. Macrolide antibiotics: current and future uses. Exp Opin Pharmacother 2004; 5: 541–550.
   PubMed Web of Science ®Google Scholar
• Carr RR, Nahata MC. Azithromycin for improving pul-monary function in cystic fibrosis. Ann Pharmacother 2004; 38 (9): 1520–1524.
   PubMed Web of Science ®Google Scholar
• De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syn-drome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibrosis 2003; 2 (2): 72–75.
   PubMedGoogle Scholar
• Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains in patients with cystic fibrosis reveals high proportions of hypermutator strains. J Infect Dis 2003; 187: 1709–1716.
   PubMed Web of Science ®Google Scholar
• Maeda K, Mikasa K, Konishi M, et al. Acute exacerba-tions due to Streptococcus pneumoniae in chronic lower res-piratory infections during long-term macrolide therapy. Kansenshogaku Zasshi 2001; 75: 846–850.
   PubMedGoogle Scholar
• Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995; 23: 316–321.
   PubMedGoogle Scholar